■非酒精性脂肪性肝病(NAFLD)是一种常见的肝脏疾病,影响全球25%-40%的人口。NAFLD传统上与肥胖和代谢紊乱有关。NAFLD也会影响非肥胖个体,称为“精益NAFLD”(LN),他们表现出身体瘦弱和代谢性肥胖的矛盾组合。导致LN的因素尚不清楚,需要进一步研究。本分析旨在了解与肥胖NAFLD(ON)人群相比,LN的患病率和代谢特征。
■这项荟萃分析搜索了各种数据库,直到2023年8月1日。纳入标准涉及比较LN与超重/肥胖NAFLD的观察性研究。数据提取包括基线特征,疾病发生,代谢概况,和临床参数-统计分析采用计算风险比(RR)和标准平均差异。
■分析了25项研究。在NAFLD(RR0.27,95%置信区间(CI)0.14-0.52,p=<0.0001)和总(RR0.27,95%CI0.15-0.51,p<0.0001)人群中,LN与较低的患病率相关。LN具有较低的糖尿病(RR0.78,95%CI0.71-0.87,p<0.00001),血脂异常(RR0.87,95%CI0.79-0.95,p=0.002),高血压(RR0.80,95%CI0.74-0.87,p<0.00001),与ON患者相比,代谢综合征(RR0.45,95%CI0.31-0.64,p<0.00001)。LN组的血脂谱,血压,与ON相比,其他临床参数较好。
■在瘦和非瘦个体中,NAFLD的患病率因地区而异。我们的分析表明,LN与低代谢性疾病有关,空腹血糖,血压,与ON相比,脂质分布更有利。
非酒精性脂肪性肝病(NAFLD)是一种普遍的肝脏疾病,影响了全球相当一部分人口,通常与肥胖和代谢紊乱有关。然而,NAFLD患者的一个子集,称为“精益NAFLD”(LN),尽管存在代谢性肥胖,但仍表现出身体瘦弱,从而挑战了传统的关联。造成这种情况的因素还没有得到很好的理解,提示这项荟萃分析探索与肥胖NAFLD(ON)人群相比,LN的患病率和代谢特征。这项研究,进行到8月1日,2023年,分析了25项符合纳入标准的研究,其中涉及比较LN与超重/肥胖NAFLD的观察性研究。数据提取包括基线特征,疾病发生,代谢概况,和临床参数。统计分析利用风险比(RR)和标准均值差异。结果表明,在NAFLD和一般人群中,LN与明显较低的患病率相关。LN显示糖尿病(DM)发生率较低,血脂异常,高血压,与代谢综合征相比。此外,LN组表现出更有利的脂质分布,血压,和其他临床参数与ON组相比。总之,NAFLD的患病率在不同地区的瘦肉和非瘦肉个体之间存在差异.荟萃分析显示,LN与较低的代谢性疾病发生率有关,降低空腹血糖水平,降低血压,与ON组相比,脂质分布更有利。这些发现为LN的独特代谢特征提供了有价值的见解,阐明在理解和管理NAFLD方面进一步研究和临床考虑的潜在途径。
UNASSIGNED: Non-alcoholic fatty liver disease (NAFLD) is a common liver condition affecting 25%-40% of the worldwide population. NAFLD is traditionally related to obesity and metabolic disorders. NAFLD can also affect non-obese individuals, termed \"lean NAFLD\" (LN), who exhibit a paradoxical combination of physical leanness and metabolic obesity. Factors contributing to LN remain unclear, necessitating further research. This analysis aims to understand LN\'s prevalence and metabolic characteristics compared to obese NAFLD (ON) populations.
UNASSIGNED: This meta-analysis searched various databases until August 1, 2023. Inclusion criteria involved observational studies comparing LN with overweight/obese NAFLD. Data extraction included baseline characteristics, disease occurrence, metabolic profile, and clinical parameters-statistical analysis employed calculating risk ratios (RR) and standard mean differences.
UNASSIGNED: Twenty-five studies were analyzed. LN is associated with lower prevalence in both NAFLD (RR 0.27, 95% confidence interval (CI) 0.14-0.52, p = <0.0001) and total (RR 0.27, 95% CI 0.15-0.51, p < 0.0001) population. LN had lower diabetes mellitus (RR 0.78, 95% CI 0.71-0.87, p < 0.00001), dyslipidemia (RR 0.87, 95% CI 0.79-0.95, p = 0.002), hypertension (RR 0.80, 95% CI 0.74-0.87, p < 0.00001), and metabolic syndrome (RR 0.45, 95% CI 0.31-0.64, p < 0.00001) compared to those with ON. The LN group\'s lipid profile, blood pressure, and other clinical parameters were favorable compared to ON.
UNASSIGNED: The prevalence of NAFLD among lean and non-lean individuals varies by region. Our analysis revealed that LN is associated with lower metabolic diseases, fasting blood sugar, blood pressure, and a more favorable lipid profile compared to ON.
NAFLD prevalence and its characteristics among obese vs lean population Non-alcoholic fatty Liver Disease (NAFLD) is a prevalent liver condition affecting a substantial portion of the global population, commonly linked to obesity and metabolic disorders. However, a subset of individuals with NAFLD, termed “lean NAFLD” (LN), challenges the conventional association by presenting with physical leanness despite metabolic obesity. The factors contributing to this condition are not well understood, prompting this meta-analysis to explore the prevalence and metabolic characteristics of LN compared to obese NAFLD (ON) populations. The study, conducted through August 1st, 2023, analyzed 25 studies meeting inclusion criteria, which involved observational studies comparing LN with Overweight/Obese NAFLD. Data extraction included baseline characteristics, disease occurrence, metabolic profiles, and clinical parameters. Statistical analysis utilized risk ratios (RR) and standard mean differences. The results indicated that LN is associated with a significantly lower prevalence in both the NAFLD and general populations. LN demonstrated lower occurrences of diabetes (DM), dyslipidemia, hypertension, and metabolic syndrome compared to ON. Additionally, the LN group exhibited a more favorable lipid profile, blood pressure, and other clinical parameters in comparison to the ON group. In conclusion, the prevalence of NAFLD varies among lean and non-lean individuals across different regions. The meta-analysis revealed that LN is linked to a lower occurrence of metabolic diseases, lower fasting blood sugar levels, lower blood pressure, and a more favorable lipid profile compared to those with ON. These findings contribute valuable insights into the distinct metabolic characteristics of LN, shedding light on potential avenues for further research and clinical considerations in the understanding and management of NAFLD.